Ethnic differences in beta cell function occur independently of insulin sensitivity and pancreatic fat in black and white men

Meera Ladwa,1 Oluwatoyosi Bello,2 Olah Hakim,2 Fariba Shojaee-Moradie,3 Maria Linda Boselli,4 Geoff Charles-Edwards,5 Janet Peacock6,6
A Margot Umpleby,5 Stephanie A Amiel,1 Riccardo C Bonadonna,7,8 Louise M Goff2

ABSTRACT

Introduction It is increasingly recognized that type 2 diabetes (T2D) is a heterogeneous disease with ethnic variations. Differences in insulin secretion, insulin resistance and ectopic fat are thought to contribute to these variations. Therefore, we aimed to compare postprandial insulin secretion and the relationships between insulin secretion, insulin sensitivity and pancreatic fat in men of black West African (BA) and white European (WE) ancestry.

Research design and methods A cross-sectional, observational study in which 23 WE and 23 BA men with normal glucose tolerance, matched for body mass index, underwent a mixed meal tolerance test with C peptide quantifying intrapancreatic lipid (IPL), and a hyperinsulinenemic-euglycemic clamp to measure whole-body insulin sensitivity.

Results Postprandial insulin secretion was lower in BA versus WE men following adjustment for insulin sensitivity (estimated marginal means, BA vs WE: 40.5 (95% CI 31.8 to 49.2) vs 56.4 (95% CI 48.9 to 63.8) × 10^3 pmol/m^2 body surface area × 180 min, p=0.008). There was a significantly different relationship by ethnicity between IPL and insulin secretion, with a stronger relationship in WE than in BA (r=0.59 vs r=0.39, interaction p=0.036); however, IPL was not a predictor of insulin secretion in either ethnic group following adjustment for insulin sensitivity.

Conclusions Ethnicity is an independent determinant of beta cell function in black and white men. In response to a meal, healthy BA men exhibit lower insulin secretion compared with their WE counterparts for their given insulin sensitivity. Ethnic differences in beta cell function may contribute to the greater risk of T2D in populations of African ancestry.

INTRODUCTION

Populations of black African (BA) ethnicity have a higher prevalence1 2 of type 2 diabetes (T2D) compared with those of white European (WE) ethnicity. While there is evidence that part of the disparity is due to environmental and cultural factors such as socioeconomic status, diet and rates of obesity, the latter particularly in African-American women,3-5 studies which adjust for these variables have found persistently higher rates of T2D in BA populations.6 7

Not only is the prevalence of T2D in BA higher compared with the general population, there are also distinctive features in...
Metabolism

their phenotype. BA develop T2D at an earlier age (up to 10 years younger) and at a lower body mass index (BMI) than WE, with modeling of UK Biobank data demonstrating that the risk of T2D in a WE subject with a BMI of 30 kg/m² is equivalent to the risk in a BA subject with a BMI of 26 kg/m². BA exhibit a more aggressive phenotype of disease, with poorer glycemic control at diagnosis and higher rates of complications. They may have poorer responses to certain standard therapies and are more likely to have atypical presentations of T2D such as ketosis-prone diabetes. These differences have important implications for screening, diagnosis and effective treatment in this ethnic group.

Physiological studies have identified characteristic features of insulin dynamics in BA ancestry populations which may help account for some of these differences. Healthy BA subjects are reported to exhibit ‘beta cell upregulation’, with hypersecretion of insulin in excess of what is required to overcome their prevailing insulin resistance. It has also been shown that in BA subjects, intrapancreatic lipid (IPL) is more strongly associated with greater compensatory insulin secretion and is a better predictor of glucose intolerance compared with other ethnic groups.

However, the majority of these studies have been undertaken in African-American subjects and it is not known whether their findings can be equally applied to other populations of African ancestry, who are of diverse genetic admixture and who may have been exposed in utero or early life to undernutrition rather than energy excess. Furthermore, study methodologies may have a significant impact on the findings made. Beta cell hypersecretion in BA has been demonstrated largely using intravenous glucose stimulation techniques, but the intravenous route does not take account of the effects of factors such as neural and gut signals (including the incretin system), protein and fat ingestion, carbohydrate absorption rates, or first-pass splanchnic glucose extraction rates, all of which influence the complex dynamic system of beta cell insulin response in vivo. Second, multiple studies which have reported insulin hypersecretion in BA populations are based on measurements of peripheral insulin concentrations only. Insulin clearance is lower in BA compared with WE subjects; therefore measurement of peripheral insulin levels alone may overestimate beta cell insulin secretion in BA populations. The measurement of C peptide, which enables the effect of insulin clearance to be taken into account, is necessary when assessing beta cell function in this ethnic group.

Hence, our aim was to assess beta cell insulin secretion and its relationship with pancreatic fat in healthy men of black West African and white Northern European ethnicity using physiological methods which account for insulin clearance. To our knowledge, this is the first examination of the relationship between beta cell function and IPL in healthy BA adults which uses modeled C peptide data from mixed meal tolerance test (MMTT).

MATERIALS AND METHODS

Study design

The data were collected as part of ‘Soul-Deep II’, a cross-sectional study of ethnic differences in the development of T2D in men from two ethnic groups, WE and BA. Metabolic assessments were performed at the Clinical Research Facility, King’s College Hospital, London, UK, while MRI took place at Guy’s Hospital, London, UK. Recruitment of subjects and data collection took place between April 2016 and May 2018. Recruitment was carried out through advertising in the local press and via general practice surgeries. All subjects provided written informed consent prior to the study.

Subjects

Subjects were invited to a screening assessment at the Clinical Research Facility at King’s College Hospital, following a 10-hour fast, in order to undertake a screening questionnaire, anthropometric measurements and a 2-hour 75g oral glucose tolerance test. Eligible subjects self-identified as either white (Northern) European or black (West) African (reporting four grandparents in the relevant ethnic group) and were normally glucose-tolerant according to the WHO criteria. Anthropometric measurements included height, weight, waist circumference and seated blood pressure.

Exclusion criteria were a diagnosis of diabetes or impaired glucose tolerance; treatment with oral hypoglycemics, glucagon-like peptide 1 analogs, insulin, systemic steroids or beta blockers; any condition or medication considered by the investigators to have significant impact on the study protocol or outcomes; serum creatinine of 1.5 mmol/L; serum alanine transaminase level >2.5 fold above the upper limit of the reference range; and sickle cell disease (trait permitted). Participants were instructed to refrain from (1) strenuous physical activity for 48 hours, (2) alcohol consumption for 24 hours, and (3) food and drink (other than water) for at least 10 hours prior to the study visits. Study visits were completed in random order with a minimum of 7 days between visits. Participants were mandated to complete all study visits within a maximum period of 6 months.

MMTT assessment of insulin secretion

Following an overnight fast, a cannula was inserted into the antecubital fossa vein of the subject’s non-dominant arm and two fasting blood samples drawn 10 min apart (−10, 0). A specified volume of Ensure Plus milkshake (63% carbohydrate, 22% protein and 15% fat) (Abbott Nutrition, UK) was calculated based on six caloric values (-10, 0). A specified volume of Ensure Plus milkshake (63% carbohydrate, 22% protein and 15% fat) (Abbott Nutrition, UK) was calculated based on six caloric values (-10, 0). A specified volume of Ensure Plus milkshake (63% carbohydrate, 22% protein and 15% fat) (Abbott Nutrition, UK) was calculated based on six caloric values (-10, 0).
Hyperinsulinemic-euglycemic clamp assessment of insulin sensitivity

The method has been reported.27 In brief, participants were admitted to the Clinical Research Facility following an overnight fast and weighed in light clothing. Blood samples were taken at −30, −20, −10 and 0 min for basal assessments. A 240 min two-step clamp began at 0 min. Euglycemia (5.0 mmol/L) was achieved using variable rate 20% (wt/vol) dextrose. Blood was drawn at 150, 180, 210, 220, 230 and 240 min for assessment of plasma glucose concentration and insulin concentration. Whole-body insulin sensitivity was assessed in the second half of the 240 min clamp. High-dose insulin phase; 40 mU/m2 body surface area/min)

During the meal test, mean (endogenous) insulin clearance was calculated according to the following formula30:

$$\text{Clearance}_{\text{ins}} = \frac{\text{AUC}_{\text{ISR}}}{\text{AUC}_{\text{ISR}} + (I_{\text{final}} - I_{\text{basal}}) \cdot MRT_{\text{ins}}}$$

where AUCISR is the area under the curve of insulin secretion rate, AUCins is the area under the curve of insulin concentration, Ifinal is the insulin concentration at the end of the study, Ibasa is the insulin concentration at the beginning of the study, and MRTins is the mean residence time of insulin, which was assumed to be 18 min as reported in Navalesi et al.31

<table>
<thead>
<tr>
<th>Table 1 Clinical characteristics of study participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>BA (n=23)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Weight (kg)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
<tr>
<td>Waist circumference (cm)</td>
</tr>
<tr>
<td>Fasting glucose (mmol/L)</td>
</tr>
<tr>
<td>Hba1c (mmol/mol)</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
</tr>
</tbody>
</table>

Values reported are from the participant screening visit. Data are presented as mean (SD). Differences between the two ethnic groups determined using independent samples t-tests.

Biochemical analyses

Plasma glucose concentrations were determined by an automated glucose analyzer (2300 STAT Glucose Analyzer, Yellow Springs Instrument, Ohio, USA); serum insulin concentrations by immunoassay using chemiluminescent technology (ADVIA Centaur System, Siemens Healthcare, Camberley, UK); serum C peptide concentrations by radioimmunoassay (Millipore, Hertfordshire, UK); GLP-1 and GIP (total) concentrations by fluorescent ELISA methods (EGLP-35K and EZHGIP-54K, Merck Millipore, UK); plasma glucagon by immunoassay (Meso Scale Discovery, Maryland, USA); and NEFA concentrations by enzymatic colorimetric assay (Wako Diagnostics, Richmond, Virginia), on an automated clinical chemistry analyzer (ILab 650; Instrument Laboratories, Holliston, Massachusetts).

MRI assessment of IPL and visceral fat

The MRI protocol has been reported.28 In brief, a Dixon-based MRI sequence was used on a 1.5 Tesla Siemens scanner to obtain images from the neck to the knee (excluding the arms), and 384 contiguous, axial T1-weighted, gradient-echo images with a slice thickness of 3 mm were acquired, from which fat and water images were produced as part of the Dixon sequence. MRI data were analyzed using the open source image analysis software Horos (V.1.1.7) by a single analyst who was blinded to clinical data.

IPL was measured by selecting three circular regions of interest (ROIs) of approximately 1 cm², placed on each of the head, body and tail regions of the pancreas. In each ROI, pancreatic fat fraction was quantified using the formula:

$$\text{%IPL} = \left( \frac{F}{F+W} \right) \times 100$$

where F is the pixel signal intensity of the fat image and W is the pixel signal intensity of the water image. Mean IPL was calculated as the mean of the head, body and tail IPL.

Areas of visceral adipose tissue were quantified from an axial MRI at the L4–L5 spinal anatomical position.
## Statistical analysis

Data were collected as part of the SouL-Deep II study, which included 20 samples per group to allow the detection of a difference of 1 SD with a power of 90% and two-sided significance in the primary outcome variable of beta cell insulin secretory function. Log transformation was used on skewed variables that showed a significant deviation from normality to achieve a normal distribution prior to the use of parametric tests. Significance of differences in variables between the two ethnic groups was made using independent samples t-tests. Insulin clearance was adjusted for insulin sensitivity (M/I) with one-way analysis of covariance.

The strength of linear relationships between variables of interest was assessed using Pearson’s correlation. Interactions by ethnicity were assessed using a linear regression with ethnicity*IPL. Partial correlation analysis controlling for M/I was performed.

A multiple regression model was run to predict insulin secretion (AUCISR) with covariates of ethnicity, insulin sensitivity (M/I) and IPL. Analyses were conducted with SPSS V.25.0, and p values <0.05 were considered statistically significant.

### RESULTS

#### Participant characteristics

The characteristics of the 23 BA and 23 WE participants are presented in table 1. Nine out of 23 BA men were born in either Nigeria or Ghana, with the remainder born in the UK. The two ethnic groups were similar in age, weight and BMI and showed no differences in fasting glucose, blood pressure or low-density lipoprotein (table 1). BA men had lower fasting triglyceride levels (table 1) and lower visceral fat (table 2).

### Beta cell insulin secretory function

The glucose, insulin and C peptide responses to the meal test are shown in figure 1. There were no ethnic differences in the fasting or postprandial responses (iAUC) of glucose, insulin, C peptide or beta cell insulin secretion (AUCISR) (figure 1, table 2). However,
after adjusting for insulin sensitivity (M/I), beta cell insulin secretion (AUC$_{ISR}$) was lower in BA men (estimated marginal mean in BA vs WE: 40.5 (95% CI 31.8 to 49.2) × 10$^3$ vs 56.4 (95% CI 48.9 to 63.8) × 10$^3$ pmol/m$^2$ body surface area × 180 min, p=0.008).

### Insulin clearance

The mean whole-body endogenous insulin clearance was significantly lower in BA men before and after adjustment for insulin sensitivity (M/I) (p=0.006).

### Whole-body insulin sensitivity

As previously reported, there were no significant ethnic differences in mean whole-body insulin sensitivity (expressed as M/I, included in table 2 for reference).

### Pancreatic fat

As previously reported, there were no significant ethnic differences in mean IPL (included in table 2 for reference).

### Incretin, glucagon and NEFA responses

Fasting and postprandial GIP, GLP-1, glucagon and NEFAs are shown in table 2; there were no ethnic differences in either the fasting or postprandial responses.

### Relationships between beta cell insulin secretory function and IPL

IPL was positively correlated with endogenous insulin secretion (AUC$_{ISR}$; r=0.59, p=0.003) in WE men; however, this correlation was not statistically significant in BA men (r=0.32, p=0.206) and a significant interaction by ethnicity was found (interaction test, p=0.036; figure 2A). Following adjustment for insulin sensitivity (M/I), there was no significant association between IPL and insulin secretion in either WE men (r=−0.067, p=0.767) or BA men (r=0.063, p=0.816). IPL was negatively correlated with insulin sensitivity in WE alone (r=−0.68, p<0.005), but there was no interaction by ethnicity (p=0.114) (figure 2B).

---

**Figure 1** Plasma (A) glucose, (B) insulin and (C) C peptide responses by ethnic group during the mixed meal tolerance test (data shown are mean and SD). BA, black African; WE, white European.

**Figure 2** Relationships between IPL and (A) insulin secretion and (B) insulin sensitivity by ethnicity. AUC$_{ISR}$, area under the curve of beta cell insulin secretion rate; BA, black African; BSA, body surface area; FFM, fat-free mass; IPL, intrapancreatic lipid; M/I, insulin sensitivity corrected for insulin concentrations; WE, white European.
A linear multiple regression model was run to predict insulin secretion (AUC_{ISR}), with ethnicity, pancreatic fat (IPL) and insulin sensitivity (M/I) as covariates (model 1; see table 3). Overall, the model ($r^2=0.728$) significantly predicted insulin secretion ($p<0.005$); both insulin sensitivity ($p=0.005$) and ethnicity ($p=0.01$) were independent predictors of insulin secretion, but pancreatic fat did not contribute significantly to the variation. Tests for multicollinearity between these variables were within tolerance levels (all variance inflation factors <2.0). Inclusion of age and visceral fat as covariates (model 2) did not significantly alter the model outputs.

### DISCUSSION

#### Role of IPL in beta cell insulin secretion in WE and BA men with normal glucose tolerance

The role of pancreatic steatosis in metabolic disorders has received much attention, with the observation of the recovery of beta cell function and the reversal of T2D in association with the mobilization of pancreatic fat.\(^{32}\) There is evidence that the accumulation of intracellular triglyceride induces metabolic stress in the beta cells of the pancreas, leading to beta cell dysfunction and apoptosis.\(^{33,34}\) Clinical studies have also demonstrated an association between levels of IPL and impaired insulin responses in vivo.\(^{17,35,36}\)

In this context, the pathogenesis of glucose intolerance in BA populations appears paradoxical, as they demonstrate a relatively higher prevalence of T2D,\(^{1,2}\) despite lower levels of pancreatic fat when compared with WE populations.\(^{17,37,38}\) We observed a positive correlation between IPL and insulin secretion in WE men, which was not found in BA men. However, following adjustment for the impact of insulin sensitivity, the association between IPL and insulin secretion was not significant in either ethnic group. In this study, with the acknowledgment that this was a healthy and non-obese population, pancreatic fat appears to be a proxy of insulin sensitivity and plays a surrogate role rather than directly affecting beta cell function. The role of IPL in the determination of beta cell function remains disputed, and other clinical studies have also failed to find a direct relationship in multiple ethnic groups,\(^{37,39-42}\) regardless of glucose tolerance status.

In contrast to our findings, Szczepaniak et al\(^{17}\) found that in BA subjects without diabetes, small increments in pancreatic fat were accompanied by a large linear increase in insulin secretion. They suggested that the strong relationship they observed between pancreatic triglyceride and insulin secretion in African ancestry adults was consistent with free fatty acid stimulation of the beta cell, either directly or secondarily to the promotion of insulin resistance.\(^{17}\) This was not the case in our subjects, in keeping with other investigations,\(^{37}\) despite the comparable numbers of participants. The reasons for our contrasting findings may be related to the populations under investigation; our BA subjects were mildly overweight with a mean BMI of 26.7 (SD=3.6) kg/m\(^2\), while the BA subjects in Szczepaniak et al\(^{17}\) were obese with a mean BMI of 32.2 (SD=2.2) kg/m\(^2\). Different techniques were used in the two studies; we used fat-water MRI to measure pancreatic fat fraction rather than magnetic spectroscopy; the former may be a superior modality for fat quantification owing to the irregular size and morphology of the pancreas.\(^{43}\) We modeled C peptide responses following an MMTT in place of using AIRg without C peptide responses following an MMTT in place of using AIRg as a measure of insulin secretory response. The use of AIRg without C peptide measurement may overestimate beta cell insulin secretion due to the significantly lower rates of insulin clearance in subjects of African ancestry\(^{21,24}\), hence, our methods overcame this particular limitation. Lastly, we adjusted our findings for insulin sensitivity, enabling examination of the relationship between IPL and insulin secretion while taking prevailing insulin sensitivity into account as a confounding factor.

### Ethnic comparison of postprandial insulin secretion

In BA subjects with both normal glucose tolerance and T2D, studies have consistently recognized a hyperinsulinemic response to glucose in comparison with their WE peers.\(^{41,42,44-46}\) While the hyperinsulinemia of BA populations is in part a compensation for insulin resistance, they also appear to have an exaggerated beta cell response, with excessive insulin secretion independent of insulin sensitivity.\(^{14-16,47}\) Such an observation has led to the hypothesis of ‘upregulated beta cell function’ in BA subjects, whereby the beta cell appears to be excessively responsive to glucose.\(^{14,47,48}\)

By contrast, in this study we found that there was no evidence of postprandial insulin hypersecretion in BA men and, against our expectations, insulin secretion was lower in BA compared with WE men following adjustment for insulin sensitivity. Furthermore, the peripheral

<table>
<thead>
<tr>
<th>Model 3, R(^2)=0.736</th>
<th>Ethnicity</th>
<th>-0.27</th>
<th>-2.5</th>
<th>0.021</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Insulin sensitivity</td>
<td>-0.88</td>
<td>-6.7</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td></td>
<td>IPL</td>
<td>0.036</td>
<td>0.28</td>
<td>0.785</td>
</tr>
<tr>
<td></td>
<td>VAT</td>
<td>0.002</td>
<td>-0.78</td>
<td>0.439</td>
</tr>
<tr>
<td></td>
<td>Age</td>
<td>0.101</td>
<td>0.87</td>
<td>0.390</td>
</tr>
</tbody>
</table>

AUC_{ISR}, area under the curve of beta cell insulin secretion rate; IPL, intrapancreatic lipid; VAT, visceral adipose tissue.
insulin response to oral nutrients in BA subjects did not 
replicate the very marked hyperinsulinemia both we and 
others have seen in response to intravenous glucose 
challenges in this ethnic group and indeed in these same 
study subjects. The absence of hyperinsulinemia in BA in 
response to a mixed meal—in comparison with the 
profound hyperinsulinemia of the same study subjects 
response to intravenous glucose—has also been 
reported elsewhere.

The discrepancy may be explained by the multiple vari-
ables which do not come into play during intravenous 
glucose stimulation tests, predominantly gut signals, 
although in this study no significant ethnic differences 
were found in either fasting or postprandial GLP-1 or 
GIP. Intravenous and oral challenges also differ in the 
magnitude, duration and kinetics of the glycemic load 
which is delivered to the beta cell and which during the 
MMTT is not under direct control of the investigator. 
Evidence for beta cell hypersecretion in BA is far more 
variable following oral compared with intravenous tests,
perhaps because of these factors. None of the studies to 
date which have used the MMTT have shown hyperse-
cretion of total endogenous insulin in BA adults, while 
multiple investigators have documented relatively lower 
C peptide responses in response to oral glucose in BA 
subjects. Therefore, the preponderance of intra-
venous studies in the literature may not be wholly repre-
sentative of the underlying physiology of BA populations.

Examining the data following adjustment for insulin 
sensitivity, it appears that BA men exhibit lower beta cell 
insulin secretion during the meal in the context of lower 
insulin clearance, thereby maintaining a postprandial 
glucose and insulin profile very similar to that of WE 
men. The lower rates of insulin clearance in BA subjects, 
a widely and consistently reported phenomenon, may 
from this perspective be an appropriate and adaptive 
response to maintain peripheral insulin levels in the face 
of lower beta cell insulin secretion. We have previously 
demonstrated comparatively greater insulin secretory 
deficits in BA compared with WE men with T2D. We 
postulate that the comparatively reduced insulin secre-
tion in healthy BA men may contribute to their risk of 
glucose intolerance should insulin resistance develop, a 
hypothesis that has also been proposed by others.

The reasons for the marked differences between our 
study findings and many others should be addressed. 
The majority of the literature in this area pertains to 
African-American populations (30 out of 41 studies in a 
systematic review), with relatively few studies in other 
populations of African ancestry; our participants were 
strictly of direct West African ancestry, reporting both 
parents and four grandparents born in countries of West 
Africa (Ghana and Nigeria). Differences in both genetic 
traits and environment (such as diet and obesity rates) 
may underlie distinct metabolic phenotypes in BA. A 
recently identified novel genomic locus associated with 
T2D in a population consisting of Nigerians, Ghanaians and 
Kenyans is linked to beta cell apoptosis and impaired 
insulin secretory responses, and the typical phenotype 
of sub-Saharan Africans with T2D is leaner, younger and 
characterized by insulin deficiency. A comparative 
study has identified insulin responses two to three times 
higher in African-Americans without diabetes compared 
with native Nigerians, while insulin deficiency rather 
than insulin hypersecretion has been identified in 
healthy black South Africans compared with their white 
counterparts. In accordance with these observations, it 
is hypothesized that indigenous BA populations are 
more vulnerable to beta cell dysfunction, possibly due 
to the transgenerational effects of perinatal malnutrition.

Sex differences in BA populations may also come 
into play. The preponderance of literature in this area 
pertains to women, who make up approximately 75% 
of BA subjects studied. For example, in contrast to 
our findings, Chung et al found a relative peripheral 
hyperinsulinemia in African immigrant/African-
American women in response to a mixed meal. This 
may be explained by different responses to glucose in 
BA men and women, with studies consistently finding 
greater hyperinsulinemia in women. We note with 
interest that in a recent investigation by Armiyaw et al it 
was only the African-American women who contributed 
to ethnic differences observed in beta cell responsivity, 
not the men. As their study was neither designed nor 
powered to examine interactions by sex, Armiyaw et al 
rightly advised caution when interpreting these findings.

Further work examining the interactions between sex 
and ethnicity in BA groups is warranted.

Strengths and limitations
The strengths of this study include the well-matched, 
strictly characterized subject groups and the use of a 
physiological method, the mixed meal test, to assess 
insulin secretory function. Another strength is the use 
of sophisticated techniques, including C peptide modeling 
and the reference standard hyperinsulinemic-euglycemic 
clamp, to determine beta cell function in the context of 
insulin sensitivity and to take ethnic differences in insulin 
clearance into account. In terms of limitations, while the 
study was powered for the main outcome variable of beta 
cell insulin secretion, we were not powered to examine 
the associations between variables and therefore we 
may have been unable to detect some relationships. 
We also acknowledge that, as the study was performed 
in men only, there are limitations to its generalizability; 
however, the majority of the literature on ethnic differ-
ences between WE and BA has examined women and 
therefore our choice to study men only was a conscious 
attempt to address this potential bias in the literature.

CONCLUSIONS
This detailed metabolic investigation of a well-matched 
group of normally glucose-tolerant men of European and 
African ancestry found that healthy black West African 
men do not hypersecrete insulin in response to a meal
stimulus; indeed following adjustment for insulin sensitivity, both their endogenous insulin secretion and insulin clearance rates are lower in comparison with their WE counterparts, resulting in similar postprandial systemic insulin and glucose profiles in both ethnic groups. While ethnicity and insulin sensitivity were independently associated with insulin secretion rates, pancreatic fat content was not.

We recognize that our findings run counter to much of the literature, where the consensus is that BA populations hypersecrete insulin and that pancreatic fat is a powerful determinant of their beta cell function; emerging evidence, however, shows that these established findings are not necessarily as consistent as initially thought. In some African ancestry populations, a relative deficiency of beta cell insulin secretion in the context of their insulin sensitivity may contribute to their risk of developing glucose intolerance. A better understanding of ethnic-specific differences in metabolism in both health and early disease will be key to refining prevention and treatment options, allowing an evidence-based prediction of responses which can then be tested in interventional studies.

Acknowledgements The authors would like to thank A Pernet, B Wilson and M Henderson-Wilson (Diabetes Research Group, King’s College Hospital, London, UK) for assisting with the metabolic assessments; T Dew (Viaspath, King’s College Hospital) for assistance with sample processing and laboratory analysis; L Coppin and N Jackson (University of Surrey, Guildford, UK) for assistance with analysis of the glucose enrichments; E Giumsa (Clinical Research Facility, King’s College Hospital) for accommodating participant visits; the staff of the Clinical Research Facility at King’s College Hospital for help in performing the studies; and the study participants for their time and commitment.

Contributors LMG formulated the research question, designed the study, and supervised the data collection and interpretation. SAA formulated the research question and designed the study. JP formulated the research question, designed the study, and provided statistical advice. AMU formulated the research question and designed the study. RCB supervised the modeling analysis and contributed to interpretation. OB supervised the data collection, performed the metabolic assessments and undertook data analysis. FS-M supervised the data collection and undertook data analysis. ML supervised the data collection, performed the metabolic assessments, undertook data analysis and interpretation, and drafted the manuscript. OH undertook MRI data analysis. GC-C coordinated MRI data acquisition. MLB undertook modeling analysis. All authors contributed to the intellectual content and reviewed the final version of the submitted manuscript. LMG is the guarantor of this work, had full access to all the data and takes full responsibility for the integrity of the data and the accuracy of data analysis.

Funding This work was funded by a Diabetes UK project grant (14/0004967). JP is supported by the NIHR Biomedical Research Centre based at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London and is an NIHR Senior Investigator.

Competing interests SAA has served on advisory boards for Novo Nordisk, Medtronic and Roche. The other authors declare no conflict of interest.

Patient consent for publication Not required.

Ethics approval The study was approved by the London Bridge National Research Ethics Committee (15/L0/1121).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request to LMG at louise.goff@kcl.ac.uk.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non-commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Meera Ladwa http://orcid.org/0000-0002-2775-342X
Janet Peacock http://orcid.org/0000-0002-0310-2518
Louise M Goff http://orcid.org/0000-0001-9633-8759

REFERENCES


Sharma RB, Alonso C. Lipotoxicity in the pancreatic beta cell: not just survival and function, but proliferation as well? *Curr Diab Rep* 2014;14:492.


Metabolism


